This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EGFR IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EGFR as well as the biological activity of IL2. An in vitro analysis revealed that the IL2-FuP supported mainly proliferation and lymphokine-activated killer cell activity, and IL2-FuP significantly accumulated in the tumor, which led to retardation of tumor growth. This immunocytokine was designed for treating any type of solid or non-solid cancer or malignant lymphoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-753 | Anti-EGFR Recombinant Antibody (Imgatuzumab) | Neut, ELISA, IF, IP, FuncS, FC, WB | IgG1 - kappa |
TAB-274MZ | Human Anti-EGFR Recombinant Antibody (TAB-274MZ) | FC | Humanized IgG |
TAB-297MZ | Anti-Human EGFR Recombinant Antibody (H225) | ELISA, WB | Humanized antibody |
TAB-298MZ | Anti-Human EGFR Recombinant Antibody (Hu225) | ELISA, WB | Humanized antibody |
TAB-300MZ | Human Anti-EGFR Recombinant Antibody (TAB-300MZ) | ELISA | Humanized IgG |
There are currently no Customer reviews or questions for ACFP-SH078. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.